REN and coronary artery disorder: Specifically, the deletion variant of ACE (rs7079), the C variant of Angiotensin (rs699), the C variant of the angiotensin-II receptor (rs5186), and the C-5312T variant of REN (rs12750834) have shown improved response to ACEI and Ang II receptor antagonism and decreased risk of stroke and coronary heart disease with therapy [27,28,29,30,69].